Guggenheim Rates Nuvalent (NUVL) hold, $124 Price Target

Guggenheim moved its stance on Nuvalent, Inc. to a hold rating on June 10, 2026, aligning with a cautious view from other major research firms, a 0.61% upside from the current price.

By EarningsIQ Research Desk · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 15, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 10, 2026.

Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).

NUVL Nuvalent, Inc.

$123.43 +22.40% year to date

Daily close · Jun 18, 2026

Key Points

Guggenheim analyst Brad Canino lowered his rating on Nuvalent, Inc. (NGM: NUVL) to a hold on June 10, 2026, setting a $124 price target.
Guggenheim's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
Shares traded near $123.25, hovering close to the top of their 52-week band as the biotech firm advances clinical-stage cancer therapies.
Bernstein also joined the cautious shift, downgrading the equity to Market Perform and setting a matching $124 target on June 24, 2026.

Get $NUVL trade alerts by text

We text you when insiders, Congress or big funds trade $NUVL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures

Guggenheim Shifts View on Nuvalent Shares

Guggenheim adjusted its stance on Nuvalent, Inc. (NGM: NUVL) on June 10, 2026, as analyst Brad Canino moved the equity to a hold rating. The update brings fresh perspective from the investment bank, which often covers a diverse technology and consumer roster including names like Uber Technologies and DoorDash, but now turns its lens toward the Cambridge-based biotechnology sector.

12-month forecast

$NUVL price target

Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.

Wall Street Peers Revisit Coverage

Other research houses have similarly checked their enthusiasm for the clinical-stage drug developer. On June 24, 2026, Bernstein moved its rating on the stock down to Market Perform while shifting its target to $124 from a prior level of $172. Across the broader professional community, a total of 9 analyst opinions feed into a consensus recommendation of hold, with the mean target price resting right at $124.

Equity Trades Near Peak Levels

Nuvalent shares recently changed hands at $123.25, sitting just below the upper boundary of a 52-week span that stretches from a low of $71.13 up to a high of $123.99. The equity continues to trade comfortably above its 50-day moving average of $114.66 and its 200-day moving average of $105.26. With a market capitalization hovering near $9.81 billion, the company maintains strong liquidity metrics, including a current ratio of 16.14 and a quick ratio of 15.89.

Inside the Clinical Pipeline

Headquartered in Cambridge, Massachusetts, Nuvalent focuses on creating targeted therapies for patients fighting tough forms of cancer. Its lead pipeline candidates include zidesamtinib for ROS1-positive non-small cell lung cancer, neladalkib for ALK-positive tumors, and NVL-330 targeting HER2-driven conditions. These programs aim to beat treatment resistance and brain metastases while avoiding off-target side effects.

What to Watch Next for the Firm

Market participants will keep a close eye on upcoming trial updates and corporate filings from the clinical-stage biotech firm to gauge progress on its lead candidates. Since the company is not yet profitable, it lacks a traditional P/E ratio, meaning investors rely heavily on clinical trial milestones and partnership updates with firms like Guardant Health to measure long-term value.